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OBJECTIVES The purpose of this study was to investigate whether clinical or electrophysiologic charac-
teristics could predict initial and subsequent implantable cardioverter defibrillator (ICD)
therapy.
BACKGROUND Identification of markers to predict subsequent ICD therapy and symptoms after the first
event could affect patient management.
METHODS We analyzed baseline and follow-up data on 125 ICD patients followed for 408 6 321 days.
Medications and ICD programming were not changed after first ICD therapy.
RESULTS Implantable cardioverter defibrillator therapy occurred in 58 patients (46%). Clinical features
were as follows: mean left ventricular ejection fraction (LVEF) 29% 6 15%; coronary artery
disease 84%; presenting arrhythmia with sustained monomorphic ventricular tachycardia
(SMVT) in 68%. In a multivariate analysis the relative risk for ICD therapy in patients
presenting with SMVT versus cardiac arrest (CA) was 2.57 (range, 1.32 to 5.01), and for
patients with LVEF #25%, 1.95 (1.11 to 3.45), respectively (p , 0.05). Implantable
cardioverter defibrillator therapy was not predicted by any other variable. Forty-six patients
had second ICD therapy. Mean time to second ICD therapy was only 66 6 93 days compared
with 138 6 168 days for first ICD therapy (p , 0.05). No predictor for second ICD therapy
was found. Regarding symptoms, impaired consciousness during initial ICD therapy was
predicted only by SMVT cycle length ,250 ms at electrophysiologic testing. In contrast,
symptoms were similar between first and second ICD therapy (p 5 0.0001). Of note,
ventricular tachycardia cycle length preceding first and second ICD therapy was similar (r 5
0.76, p 5 0.001).
CONCLUSIONS First ICD therapy tends to occur in patients presenting with SMVT and LVEF #25%.
Subsequent therapy occurs sooner and is unpredictable, suggesting that antiarrhythmic drug
therapy should be considered after the first symptomatic ICD therapy. Symptoms during first
ICD therapy predict subsequent symptoms, and patients presenting with SMVT and
asymptomatic first ICD therapy are at very low risk for future syncopal ICD therapy. (J Am
Coll Cardiol 2001;37:1910–5) © 2001 by the American College of Cardiology
Survivors of ventricular fibrillation and of sustained monomor-
phic ventricular tachycardia (SMVT) have a high risk of
arrhythmia recurrence, especially in the first year after the
presenting arrhythmic event. The results from the Antiar-
rhythmic Versus Implantable Defibrillator (AVID) trial (1)
and the Multicenter Unsustained Tachycardia Trial
(MUSTT) (2) demonstrated that the implantable cardioverter
defibrillator (ICD) reduced mortality compared with drug
treatment. Few data, however, are available on patient symp-
toms associated with arrhythmia recurrence with ICD therapy
(3,4), the results of which could influence the ability to resume
higher risk activity such as driving (5). Some studies have
shown a lower incidence of first ICD therapy after six to
12 months (5,6), especially in patients with left ventricular
ejection fraction (LVEF) above 25% (7). Importantly, little is
known about the probability of a second arrhythmic event and
symptoms. Thus, the purpose of our study was to investigate
which clinical or electrophysiologic characteristics could
predict if and when first and second ICD therapy would
occur and whether initial symptoms correlate with subse-
quent symptoms associated with ICD therapy.
METHODS
Patients. To exclude inappropriate shocks and to verify
that therapy delivered to an asymptomatic patient was
appropriate, only patients with an ICD with interval (Ven-
tak PRx Model 1700, 1705, 1710 and 1715, CPI, Minne-
apolis, Minnesota) or electrogram recording capability
(Cadence Model V100, V100B, V100C, Ventritex, Sylmar,
California, and Ventak PRx Model 1715, Guidant, India-
napolis, Indiana) were included. The records of 125 con-
secutive patients who had undergone implantation using
one of these ICDs for symptomatic ventricular tachycardia
(VT) or cardiac arrest and who were followed by one of the
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authors were examined. Patients in whom an ICD was
implanted prophylactically were excluded from the study.
Baseline data for each patient included gender, age, type of
heart disease, history of myocardial infarction, history of
congestive heart failure, past history of coronary artery
bypass grafting, LVEF, electrogram QRS duration and
signal-averaged electrogram. Type of presenting arrhyth-
mia, cardiac arrest (CA) or SMVT was determined. For
patients with SMVT, the arrhythmia cycle lengths and
symptoms were noted.
The electrophysiologic study (EPS) procedure has been
reported in detail (8). In patients with hemodynamically
stable SMVT, serial electrophysiologic-pharmacologic test-
ing was done. An ICD was implanted in patients who did
not have adequate response to the drugs tested. Drug
therapy at the time of the presenting arrhythmia and at
discharge was noted.
Follow-up. In a predischarge EPS, patients with hemody-
namically stable SMVT had antitachycardia pacing tested
and enabled only if the SMVT was reproducibly terminated.
After hospital discharge, patients were seen by one of the
authors (ENP, RIF) every two to six months and also after a
clinically apparent arrhythmic event. At each visit a history and
physical examination were done, and the ICD was interrogated
for new arrhythmic events. When such an event was noted, the
patient activity and symptoms at that time were recorded.
Appropriate ICD therapy was identified on the basis of device
interrogation and clinical information.
In patients not treated with an antiarrhythmic drug
(AAD) before the first ICD therapy, initiation of an AAD
was deferred until after the next ICD therapy. Similarly,
patients receiving an AAD before the first ICD therapy
continued with the same AAD.
Statistical methods. The chi-square test or the Fisher exact
test was used for analysis of categorical variables. The Student
t test or analysis of variance was used for analysis of continuous
variables as appropriate. Actuarial survival and freedom from
arrhythmia were computed by the Kaplan-Meier product limit
method (9). Survival and freedom from arrhythmia between
two groups were compared using the log-rank test (10).
Multivariate analysis was done by the Cox proportional hazard
model (11). Statistical computations were done with Statistica
for Macintosh software.
RESULTS
Baseline characteristics (Table 1). One hundred twenty-
five patients with an ICD with interval or electrogram
recording capability were followed at the Care Group
arrhythmia clinic for 408 6 321 (range, 1 to 1,277) days.
Five patients died one to 188 days after implantation (one-
and three-year survival of 95%). All deaths were due to
cardiac causes, and no death was sudden.
Thirty-nine patients (31%) were treated with AAD: 14
(36%) for atrial fibrillation (AF), 12 (31%) for VT slowing
at EPS and 13 (33%) for suppression of frequent nonsus-
tained VT. Twenty-seven patients (70%) were treated with
amiodarone, four with mexiletine, three with propafenone,
two each with quinidine and sotalol, and one with procain-
amide.
Predictors for initial ICD therapy. Fifty-eight patients
(46%) had an initial ICD therapy after 152 6 193 (range, 1 to
896) days. Actuarial freedom from initial ICD therapy is
shown in Figure 1. Clinical characteristics of patients who had
ICD therapy are shown in Table 2. Patients with LVEF
#25% had one- and two-year freedom from ICD therapy of
39% and 31% versus 57% and 52%, respectively, for patients
with LVEF .25% (p 5 0.024, log-rank test) (Fig. 2A). In
patients presenting with SMVT versus CA, one- and two-year
freedom from ICD therapy were 43% and 34% versus 62% and
52%, respectively (p 5 0.0045, log-rank test) (Fig. 2B).
Patients treated with AAD also had more ICD therapies, with
one- and two-year freedom from ICD therapy of 44% and
24% versus 53% and 50%, respectively (p 5 0.039, log-rank
test) (Fig. 2C). In contrast, treatment with a beta-blocker did
not predict ICD therapy.
In age- and gender-adjusted multivariate analysis, pre-
senting arrhythmia and LVEF #25% (but not AAD ther-
apy) were independent predictors for initial ICD therapy,
with odds ratios (95% confidence interval) for presenting
arrhythmia of SMVT 2.573 (1.321 to 5.013) and for LVEF
#25% 1.953 (1.107 to 3.447) (p , 0.05). Age, gender or
type of heart disease did not predict the time from implant
to first ICD therapy.
Abbreviations and Acronyms
AAD 5 antiarrhythmic drug
AF 5 atrial fibrillation
CA 5 cardiac arrest
EPS 5 electrophysiologic study
ICD 5 implantable cardioverter defibrillator
LVEF 5 left ventricular ejection fraction
SMVT 5 sustained monomorphic ventricular tachycardia
VT 5 ventricular tachycardia
Table 1. Baseline Clinical Characteristics of the Patients
Patient Characteristics n 5 125
Follow-up period (days) 408 6 321
Age (years) 66 6 9
Male (%) 78%
LVEF (%) 29 6 15
LVEF # 25% 52%
History of CHF (%) 59%
CAD (%) 84%
Beta-blocker therapy at hospital discharge 10%
AAD therapy at hospital discharge 31%
SMVT/CA (SMVT%) 86/39 (68%)
Death 5 (4.5%)
AAD 5 antiarrhythmic drug; CA 5 cardiac arrest; CAD 5 coronary artery disease;
CHF 5 congestive heart failure; LVEF 5 left ventricular ejection fraction; SMVT 5
sustained monomorphic ventricular tachycardia.
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Predictors for subsequent ICD therapy. In a follow-up
period of 329 6 295 (range, 7 to 1,179) days after the initial
ICD therapy, only 12 patients (21%) remained free of further
ICD therapy. No patient had ADD therapy changed
between initial ICD therapy and second ICD therapy.
There were no significant differences in clinical charac-
teristics between patients who had one or more than one
ICD therapy.
Figure 1 shows Kaplan-Meier analysis of the period from
the first to second ICD therapy. The median actuarial
freedom from ICD therapy for the second shock was
22 days, and all second shocks occurred within one year after
the initial ICD therapy. There were no significant differ-
ences in the clinical characteristics of the nine patients with
recurrence within 48 h compared with the 37 patients who
had subsequent ICD therapy .48 h later. In patients in
whom subsequent ICD therapy occurred after .48 h, mean
time to second ICD therapy was 66 6 93 days compared
with 138 6 168 days for first ICD therapy (p , 0.05). None
of the clinical predictors that predict first ICD therapy was
useful for the prediction of the next ICD therapy. Similarly,
the actuarial freedom from subsequent ICD therapy could
not be predicted by any clinical characteristics of the
patients who had the first ICD therapy. No correlation was
found between time to the first and second ICD therapy.
Symptoms associated with ICD therapy. The symptoms
during first ICD therapy are summarized in Table 3. Only
9% of the patients who presented with SMVT had syncope
during the first ICD therapy, versus 36% of the patients
who presented with CA (p , 0.05). However, 22% of
patients who presented with SMVT had near syncope
during first ICD therapy, versus none of the CA patients
(p 5 0.09).
Ventricular tachycardia cycle length induced at baseline
EPS was shorter than 250 ms in five of six patients in whom
first ICD therapy was associated with syncope (83%),
compared with 10 of 41 patients who had no syncope (24%)
(p , 0.005). Ventricular tachycardia cycle length #250 ms
at baseline EPS was noted in five of 12 patients (58%) who
had impaired consciousness (near syncope or syncope),
versus eight of 35 (23%) patients who did not (p , 0.05).
Presenting symptoms in patients with SMVT did not
correlate with symptoms during first ICD therapy (Fig. 3),
nor with any clinical variable including LVEF or the
presence of AF.
In contrast, patients tended to have similar symptoms
with the first and second ICD therapy, respectively (p 5
0.0001): syncope (6 vs. 3 syncope with the first ICD, 2 near
Table 2. Clinical Characteristics of Patients With ICD Therapy
versus No ICD Therapy
Patient Characteristics No ICD-T ICD-T p
Number 67 58 —
Follow-up period (days) 343 6 299 482 6 334 0.016
Age (years) 65 6 10 67 6 9 n.s.
Male (%) 73% 84% n.s.
LVEF #25% 42% 63% 0.025
History of CHF (%) 51% 67% n.s.







SMVT/CA (SMVT%) 39/28 (58%) 47/11 (81%) 0.006
Death 3 2 n.s.
AAD 5 antiarrhythmic drug; CA 5 cardiac arrest; CAD 5 coronary artery disease;
CHF 5 congestive heart failure; ICD-T 5 implantable cardioverter defibrillator
therapy; LVEF 5 left ventricular ejection fraction; n.s. 5 not significant; SMVT 5
sustained monomorphic ventricular tachycardia.
Figure 1. Actuarial freedom from initial versus second ICD therapy. ICD 5 implantable cardioverter defibrillator.
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syncope, 1 asymptomatic with the second), near syncope (8
vs. 6 near syncope, 2 asymptomatic), other symptoms (2 vs.
2), asymptomatic (30 vs. 28 asymptomatic, 2 syncope) (Fig.
4). In patients whose initial arrhythmia was SMVT, only
one of 25 patients who were asymptomatic with the first
ICD therapy had syncope with the second ICD therapy
(p , 0.0001). One of five patients with CA who were
asymptomatic on the first ICD therapy had syncope on the
second ICD therapy (p 5 0.07). The cycle length of VT
preceding first and second ICD therapy was similar (r 5
0.75; p 5 0.0001) (Fig. 5).
DISCUSSION
This study evaluated whether clinical or electrophysiologic
characteristics associated with patients who had first ICD
therapy added prognostic information regarding recurrence
and symptoms of subsequent ICD events. The significant
new observations noted in this study are as follows: 1)
subsequent ICD therapy occurs sooner than first ICD
therapy, and neither time nor recurrence can be predicted by
any clinical variable; 2) symptoms during first ICD therapy
predict subsequent symptoms; and 3) patients presenting
with SMVT and asymptomatic first ICD therapy are at very
low risk for future syncopal ICD therapy.
Predictors for subsequent ICD therapy. Our policy has
been to delay prescribing AAD after the first ICD therapy,
because the frequency of recurrence of sustained VT is not
known for a particular patient. Importantly, the time to the
second ICD therapy was therefore not influenced by change in
drug therapy in this study. Additional ICD therapy was
observed in 79% of the patients after the initial event. The
second ICD therapy, however, occurred much sooner than
the first, and the time to first therapy did not predict the
time to second therapy. The median actuarial ICD therapy-
free survival to the second ICD therapy was only 22 days (46
days excluding patients who had second ICD therapy within
48 h), versus 348 days for the first ICD therapy. In contrast
Figure 2. Predictors for actuarial freedom from initial ICD therapy. (A)
left ventricular ejection fraction; (B) presenting arrhythmia; (C) antiar-
rhythmic drug use. AAD 5 antiarrhythmic drugs; CA 5 cardiac arrest;
EF 5 left ventricular ejection fraction; ICD 5 implantable cardioverter
defibrillator; VT 5 ventricular tachycardia.
Figure 4. Symptoms with first ICD therapy versus second ICD therapy
(patients who had only one ICD therapy were excluded). ICD 5
implantable cardioverter defibrillator.
Table 3. Symptoms During First ICD Therapy in Patients
According to the Presenting Arrhythmia
Symptom SMVT CA Total
Syncope 4 (9%) 4 (36%) 8 (14%)
Near syncope 10 (22%) 0 10 (18%)
Other symptoms 2 (4%) 1 (9%) 3 (5%)
Asymptomatic 30 (65%) 6 (55%) 36 (63%)
Totals 46 11 57
CA 5 cardiac arrest; ICD 5 implantable cardioverter defibrillator; SMVT 5
sustained monomorphic ventricular tachycardia.
Figure 3. Presenting symptoms versus first implantable cardioverter defi-
brillator therapy symptoms in patients with sustained monomorphic
ventricular tachycardia. ICD 5 implantable cardioverter defibrillator.
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to the initial ICD therapy, actuarial freedom from subse-
quent ICD therapy of patients presenting with CA was not
significantly different from patients presenting with SMVT.
Similarly, patients treated with antiarrhythmic drugs before
initial hospital discharge did not have higher incidence of
second ICD therapy compared with first ICD therapy.
Finally, symptoms during the first ICD therapy did not
predict incidence or actuarial freedom from second ICD
therapy. Thus, an initial ICD therapy per se selects patients
who will have an approximately 80% chance of another ICD
therapy within one year. That incidence is much higher
than seen with any of the clinical variables that predict the
first ICD therapy. No clinical predictor was found for very
early (,48 h) second ICD therapy.
Although a recent paper suggested that treatment with
sotalol may reduce the frequency of ICD therapy (12), the
influence of adding or changing AAD therapy at VT recur-
rence on symptoms is unknown. Our data, however, showed
that ICD therapy without alteration of AAD treatment occurs
early and is not predictable. Thus, one should consider initia-
tion of a new AAD regimen soon after the first ICD therapy,
especially when therapy is a direct current shock and accom-
panied by syncope or near syncope (3,12).
Symptoms associated with ICD therapy. During first
ICD therapy, 14% of the patients had syncope and 17% near
syncope. Impaired consciousness (syncope or near syncope)
occurred in 30% of patients who presented with SMVT and
in 36% of CA patients. However, patients who presented
with SMVT tended to have near syncope whereas patients
who presented with CA had syncope (p , 0.05). No other
clinical baseline variable or presenting symptom predicted
symptoms of first ICD therapy. Inducible VT cycle length
#250 ms at EPS did, however, predict syncope and im-
paired consciousness at subsequent arrhythmic event.
Importantly, symptoms during the first ICD therapy
correlated highly with symptoms of the next ICD therapy
(p 5 0.0001). Only two of 30 patients who were asymp-
tomatic at the first ICD therapy had syncope with the next
ICD therapy. In patients presenting with SMVT and initial
asymptomatic ICD therapy, the probability of syncope on
the second ICD therapy was only one in 25 (4%). The fact
that we did not change AAD therapy or device setting after
the first ICD therapy, and the observation that tachycardia
cycle length during first and second ICD therapy was
similar, may explain the consistency of symptoms between
ICD therapies.
Our data differ from those of Bansch et al. (3), who found
risk factors for syncope to be LVEF #40%, chronic AF and
inducible VT with a cycle length ,300 ms. However, our
patient population differs significantly from their study (age
66 6 8 years vs. 58 6 13, LVEF 29 6 15 vs. 43 6 17,
coronary artery disease in 84% vs. 62%, inducible VT cycle
length .300 ms in 32% of VT induced vs. 46%, respec-
tively) Our study population is similar to several other major
ICD studies (1,2,13,14). Additionally, more than half of
Bansch’s patients had a change in therapy after the first
event, either by addition of drugs or by alternation of ICD
settings (3), which may have prevented subsequent syncope.
Predictors for initial ICD therapy. Using strict criteria for
appropriate ICD therapy, we found that 58 patients (46%) had
an initial ICD therapy after 152 6 193 (range, 1 to 896) days.
This is in agreement with most other studies (7,15,16).
Patients who had ICD therapy tended to have LVEF #25%
(63% vs. 42%, p 5 0.025), as noted in some (7,17–22) but not
Figure 5. Correlation between cycle length of ventricular tachycardia preceding first and second ICD therapy. ICD 5 implantable cardioverter defibrillator;
VT 5 ventricular tachycardia.
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other studies (5,15,23); patients more commonly had SMVT
(81% vs. 58%, p 5 0.006), as previously reported (15). Type of
heart disease, age and gender did not predict ICD therapy or
time from implant to first ICD therapy. Most of the ICD
therapy in our study occurred in asymptomatic patients.
Limitations. To exclude inappropriate shocks and to verify
that the therapy delivered to asymptomatic patients was
appropriate, only patients who were initially implanted with
an ICD having electrogram or RR interval recording capa-
bilities were included in our study. However, even with
intracardiac electrograms, occasional supraventricular tachy-
cardia masquerading as VT cannot be ruled out (24,25).
Patients can also have a change in cardiac function that may
alter symptoms with recurrent VT or ventricular fibrillation.
In this situation, a previously hemodynamically stable VT
may result in syncope.
One cannot predict the effect of adding an AAD on
subsequent symptoms. Although a slower VT may occur
during AAD treatment, symptoms may be unchanged or
even worsen. Thus, after a change in AAD therapy close
observation and restriction from driving appear warranted.
Conclusion. After an ICD is implanted, arrhythmia recur-
rence tends to occur early in patients treated with AAD who
have a history of SMVT and LVEF #25%. Because a second
ICD therapy occurs soon and is unpredictable, we recommend
early consideration for AAD therapy for patients who have
significant symptoms with the initial ICD event and restriction
of driving (12). A recent policy statement suggests that driving
be restricted for six months after initial ICD implant (26).
However, if the first ICD therapy is asymptomatic in a patient
with SMVT with a stable disease state, chances of syncope or
presyncope with subsequent ICD therapy is minimal, provid-
ing no change in AAD therapy is made. In these patients it
may be reasonable to consider resumption of driving with
appropriate precautions.
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